AtriCure (NASDAQ: ATRC) reported Q1 EPS of ($0.42), $0.01 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $53.2 million versus the consensus estimate of $55.5 million.

“I want to extend gratitude to our partners in the healthcare community, all of whom are taking extraordinary efforts to care for both COVID and non-COVID patients in these difficult times. As the world continues to navigate the pandemic, we have positioned our business to mitigate disruption and remain committed to supporting our people, patients, customers and communities,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “We have built a great foundation strategically, financially and operationally that will guide us to long-term growth.”

For earnings history and earnings-related data on AtriCure (ATRC) click here.